Gefitinib Used for Mesothelioma Patients

Gefitinib, a new drug to be tested by researchers at the National Cancer Institute in Bethesda, Maryland are on a look out for 40 patients with the asbestos based illness mesothelioma, the candidate who haven’t undergone surgery or radiation. Gefitinib is a new drug used in the treatment of certain kind of cancer. It is also used in the treatment of metastatic lung cancer in mesothelioma patients who underwent previously chemotherapy treatments. Gefitinib forbids cell growth in cancerous cells by mainly targeting proteins located in the cells. Proteins are usually high in cancer cells.

Malignant mesothelioma cancer

Malignant mesothelioma cancer is a rear cancerous tumor of lining of the abdomen or the lining of the lung and chest cavity which is typically due to long-term direct asbestos exposure. A large number of people diagnosed with malignant mesothelioma cancer have regularly worked on job sites where they had breathed asbestos. Research studies have relieved that asbestos may normally many diseases, from non-cancerous forms such as asbestosis, to much more dangerous diseases such as mesothelioma. This cancer typically develops between 20 to 40 years after a person's initial direct exposure to asbestos.

Asbestos

Asbestos is a naturally occurring silicate mineral with thin and long fibrous crystals with possess unique qualities.

• Asbestos was widely used throughout the 20th century by industries that were into manufacturing products and builders which required heat resistance, durability and high versatility.
• Mesothelioma often appears less-serious health conditions, making diagnosis really difficult.
• Therefore, the prognosis associated with any type of mesothelioma is quite poor, as a proper cure does not presently exist.
• Moreover the treatment options are minimal since the tumor is usually not diagnosed until it has matured within the patient’s body.

Research study

The study is conducted in the Phase II of a clinical trial that research study doctors hope will decide the efficaciousness of gefitinib for mesothelioma patients. The research mesothelioma doctors will give the participants, daily doses of an oral version of gefitinib and will be thoroughly monitored for up to four years. Gefitinib has yet to indicate decisive evidence that really proves it may improve symptoms or extend life after successful treatment in mesothelioma patients, but physicians are hopeful that this final phase of clinical trials will not only show accurate data, but will usually lead to a full Food and Drug Administration approval.

Please contact mesothelioma experts for more information!